Some recently published in vitro studies with two metabotropic glutamate 2/3 receptor (mGluR 2/3 ) agonists [(Ϫ)-2-oxa-4-aminobicyclo[3.1.0] hexane-4,6-dicarboxylic acid (LY379268) and 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740)] suggest that these compounds may also directly interact with dopamine (DA) D 2 receptors. The current in vitro and in vivo studies were undertaken to further explore this potential interaction with D 2 receptors. LY379268 and LY354740 failed to inhibit D 2 binding in both native striatal tissue homogenates and cloned receptors at concentrations up to 10 M. LY379268 and LY354740 (up to 10 M) also failed to stimulate [
g/kg i.v.), whereas aripiprazole (10 -60 mg/kg) showed up to 90% striatal D 2 receptor occupancy. LY379268 (10 mg/kg) and raclopride (3 mg/kg) blocked d-amphetamine and phencyclidine (PCP)-induced hyperactivity in wild-type mice. However, the effects of LY379268 were lost in mGlu 2/3 receptor knockout mice. In DA D 2 receptor-deficient mice, LY379268 but not raclopride blocked both PCP and d-amphetamine-evoked hyperactivity. In the striatum and nucleus accumbens, LY379268 (3 and 10 mg/kg) was without effect on the DA synthesis rate in reserpinized rats and also failed to prevent S-(Ϫ) -3-(3-hydroxyphenyl) -N-propylpiperidine-induced reductions in DA synthesis rate. Taken together, the current data fail to show evidence of direct DA D 2 receptor interactions of LY379268 and LY354740 in vitro or in vivo. Instead, these results provide further evidence for a novel antipsychotic mechanism of action for mGluR 2/3 agonists.
Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system, and the variety of its effects in the brain is regulated in part by the diversity of receptor subtypes that respond to glutamate. These receptors include both ionotropic (ligand-gated ion channels) and metabotropic (G protein-coupled) receptor families (Dingledine et al., 1999; Schoepp, 2001) . Although the ionotropic receptors were the first to be discovered and have been of significant interest as potential therapeutic targets, the metabotropic glutamate (mGlu) receptors are now also of great interest for potential pharmacotherapeutic development. There are eight mGlu receptors, which have been divided into three subgroups, group I (mGlu 1 and mGlu 5 ), group II (mGlu 2 and mGlu 3 ), and group III mGlu (mGlu 4/6/7/8 ) receptors, on the basis of molecular structure, pharmacology, and signal transduction pathways. The development of selective pharmacological tools for various mGlu receptor subtypes has enabled animal studies suggesting that these receptors may provide potential targets for the treatment of a wide variety of psychiatric and neurological disorders in humans (for reviews see, Schoepp, 2001; Niswender et al., 2005; Pilc et al., 2008) .
The potential therapeutic promise of mGlu receptor-targeted molecules was recently reinforced by the finding that LY2140023 (the prodrug of the mGlu 2/3 agonist LY404039) produced statistically significant improvements in symptoms in a Phase II trial for patients with schizophrenia (Patil et al., 2007) . Preclinical data suggest that the antipsychotic actions of mGlu 2/3 receptor agonists such as LY404039 are mechanistically distinct from present antipsychotic drugs and mediated via the selective activation of mGlu 2 receptors. For example, the ability of mGlu 2/3 receptor agonists to attenuate phencyclidine (PCP) and amphetamine (AMP)-evoked hyperactivity in mouse models of psychosis is blocked by the mGlu 2/3 receptor antagonist LY341495 (Cartmell et al., 1999; Rorick-Kehn et al., 2007) . Studies carried out in transgenic mice reveal that the antipsychotic actions of the mGlu 2/3 receptor agonists LY404039 or LY379268 are lost in mice with targeted deletions of mGlu 2 , mGlu 2/3 , but not mGlu 3 receptors (Patil et al., 2007; Fell et al., 2008; Woolley et al., 2008) , whereas antipsychotic drugs (olanzapine, risperidone, and clozapine) block PCP-induced locomotor activity in both the wild-type and mGlu 2/3 receptor knockout animals.
However, two different mGlu 2/3 receptor agonists, LY354740 and LY379268, were recently suggested to possess partial agonist activity at both the dopamine (DA) D 2 long (D 2L ) and D 2 short (D 2S ) isoforms of the dopamine D 2 receptor (Seeman and Guan, 2008; . The primary in vitro evidence used to support this claim was a relatively high affinity for displacing [ 3 H]domperidone binding in either rat striatal tissue or cloned human D 2L and D 2S receptors, and an apparent partial agonist activity as measured by the stimulation of [ 35 S]GTP␥S binding in cells expressing either cloned dopamine D 2L or D 2S receptors. K i values for LY379268 at D 2 receptors were reported to be in the range of 5 to 30 nM and between 20 and 50 nM for LY354740. Based on the structural similarities of LY404039 to LY379268 and LY354740, Seeman (2008) raised the possibility that the clinical activity of LY2140023 might be due to the actions of LY404039 at D 2 receptors rather than mGlu 2/3 receptors.
The findings reported by Seeman and co-workers (2008) of dopamine D 2 receptor affinity and partial agonist activity of LY379268 and LY354740 were surprising, because previous studies had not suggested any direct interactions with dopaminergic receptors. Thus, the current work was undertaken as an attempt to replicate the in vitro findings of Seeman and co-workers (2008) 35 S]GTP␥S in membranes expressing either human isoform. In addition, we conducted a series of behavioral and neurochemical studies that were designed to evaluate the possible interaction of mGlu 2/3 receptor agonists with D 2 receptors in vivo. Thus, we assessed in vivo striatal D 2 receptor occupancy in the rat for LY379268, LY354740 monohydrate, and the partial D 2 receptor agonist aripiprazole by using an LC/MS/MS-based method (Barth et al., 2006) . Furthermore, we compared LY379268 to the D 2 /D 3 antagonist raclopride for reversal of PCP and d-amphetamine-induced hyperlocomotion in wild-type mice or mice deficient of mGlu 2/3 receptors or DA D 2 receptors. Finally, brain DA synthesis rate in reserpinized rats (Svensson et al., 1991) was used as a sensitive in vivo neurochemical assay to study potential agonist/antagonist properties of mGlu 2/3 receptor agonists at D 2 receptors.
Materials and Methods
In Vitro Experiments. Materials. Domperidone, S-(Ϫ)-sulpiride, 3-hydroxytyramine (dopamine), raclopride, 3-(3-hydroxyphenyl Rat striata were purchased from Zivic Laboratories (Pittsburgh, PA). Rat striatal homogenates were prepared as described previously (Wainscott et al., 2005) . Rat striatal membranes were thawed, diluted to 0.085 mg/tube in binding buffer (13 mM MgCl 2 , 1.67 mM EDTA, 133 mM NaCl, and 67 mM Tris-HCl, pH 7.4), and homogenized with a polytron. hD 2L and hD 2S membranes were thawed, diluted to 0.0022 and 0.0085 mg/tube in binding buffer, respectively, and then homogenized with a polytron.
[ 3 H]Domperidone binding. The domperidone binding assays were adapted from that originally described by Grigoriadis and Seeman (1986) . Binding assays were performed in duplicate in 0.4-ml total volume. Membrane suspension (100 l) and 100 l of drug dilution were added to 200 l of binding buffer containing [
3 H]domperidone (2 nM) in minitubes. Minitubes were incubated at room temperature for 60 min. The incubation was terminated by rapid filtration through Whatman hydrophilic GF/C, 96-well filter plates that had been presoaked in 0.5% polyethylenimine. The filter plate was washed three times with ice-cold 50 mM Tris-HCl, pH 7.4. Nonspecific binding was defined by sulpiride (10 M). (Sim et al., 1995; Thomas et al., 1995) . Assays were performed in TrisHCl, MgCl 2 , EDTA, and either NaCl or NMDG to enhance partial agonist activity (Lin et al., 2006) (Harlan, Indianapolis, IN) weighing between 200 to 350 g were tested in the receptor occupancy and the dopamine synthesis rate assays. The sample sizes for each experiment were as follows: receptor occupancy, n ϭ 4 to 5 per group; dopamine synthesis rate n ϭ 6 to 12/group. Rats were group housed with standard laboratory chow and water available ad libitum. Rats were maintained on a 12-h light-dark cycle (lights on at 6:00 AM, lights off at 6:00 PM). Male mice (mGlu 2/3 double knockouts, DA D 2 knockouts, and their respective wild-type animals) weighing approximately 25 to 30 g (Taconic Farms, Germantown, NY) were tested in PCP or AMP-induced hyperlocomotion experiments (n ϭ 8 per group). Mice were housed in groups by genotype under a 12-h light-dark cycle (lights on at 6:00 AM, lights off at 6:00 PM) with food and water freely available.
Materials. LY354740 monohydrate, LY379268, and aripiprazole were synthesized at Lilly Research Laboratories. d-Amphetamine sulfate, PCP hydrochloride, quinpirole, S-(Ϫ)-3-PPP HCl, and reserpine were obtained from Sigma-Aldrich. Raclopride was purchased from Tocris Bioscience (Ellisville, MO) and dissolved in 0.9% NaCl by the drop-wise addition of 8.5% lactic acid. LY354740 monohydrate and LY379268 were dissolved in sterile 0.9% NaCl by the dropwise addition of 5 N NaOH. d-Amphetamine sulfate and phencyclidine hydrochloride were dissolved in 0.9% saline. Quinpirole and S-(Ϫ)-3-PPP were dissolved in sterile water. Aripiprazole and reserpine were dissolved in minimal quantities of dimethyl sulfoxide.
Receptor Occupancy Assay. In vivo D 2 occupancy and analysis of unlabeled raclopride levels by LC/MS/MS. Radioactivity raclopride was used as an occupancy tracer in the LC/MS/MS-based experiments to assess in vivo D 2 occupancy and was administered at an intravenous dose of 3 g/kg dissolved in sterile water (Barth et al., 2006) . To examine D 2 dose-occupancy relationships LY379268, LY354740 monohydrate, and aripiprazole were administered to groups of 4 to 5 rats pretreated with test compound or its vehicle. One hour later (90 min for aripiprazole), animals were briefly restrained and administered a low intravenous dose of unlabeled raclopride tracer via the lateral tail vein. LY379268 was administered at doses of 1, 3, and 10 mg/kg i.p. LY354740 monohydrate was administered at doses of 10, 30, and 60 mg/kg i.p. Aripiprazole was administered p.o. at doses of 10, 30, and 60 mg/kg. Fifteen minutes after the intravenous administration of the raclopride tracer rats were sacrificed by cervical dislocation, and rat brain striatum and cerebellum tissue samples were dissected, weighed, and kept on ice. Brain tissues samples were processed, and raclopride measurements were made by using a liquid chromatograph [high-performance liquid chromatography (HPLC); model 1100, Agilent Technologies, Wilmington, DE] with triple quadrapole mass spectral detection. The HPLC system used a C18 column (Zorbax Eclipse, 2.1 ϫ 50 mm, 3.5-m particle size; Agilent Technologies) with an aqueous mobile phase consisting of 32% acetonitrile with 0.1% formic acid. Raclopride was quantified after elution from the HPLC column by using an API 4000 triple quad mass spectrometer (Applied Biosystems, Foster City, CA) in positive electrospray mode using multiple reaction monitoring methods to observe the transition from parent to daughter ions with mass-to-charge ratios of 347.1 and 112.3, respectively. Chromatographic assays were calibrated by using a standard curve generated by extracting a series of brain tissue samples from nontreated animals to which known quantities of raclopride had been added. Please refer to Chernet et al. (2005) and Barth et al. (2006) for more detailed methods.
Receptor occupancy calculation. Receptor occupancy calculations were made for each animal by using the widely used ratio method (Farde et al., 1988; Kapur, 2000; Wadenberg et al., 2000) and the following equation: 100
The "Ratio t " represents the ratio of raclopride concentrations measured in the striatum to those measured in the cerebellum in individual animals pretreated with antipsychotic compounds. The "Ratio c " represents the average ratio of raclopride levels measured in the striatum to that measured in the cerebellum for the vehicle-pretreated group.
Mouse Locomotor Activity Assessment. Generation of mGlu 2/3 receptor knockout mice. mGlu 2/3 receptor knockout mice (Taconic Farms) were generated by homologous recombination as described in detail by Fell et al. (2008) . The targeting construct was injected into the R1 line of mouse embryonic stem cells. The recombinant embryonic stem cells were injected into murine C57BL/6 blastocysts, and chimeric males were mated with ICR(CD-1) females. Male offspring carrying the null allele were backcrossed for three generations (N3) with ICR(CD-1) females. N3 offspring were then interbred, and siblings homozygous for the null allele were used as founders that provided all mGlu 2 receptor knockout mice and mGlu 3 receptor knockout mice used here. Males homozygous for the null allele of mGlu 3 were intercrossed with females homozygous for the null allele of mGlu 2 to produce an intercross colony heterozygous for both mGlu 2 and mGlu 3 null alleles. Breeding of siblings from the intercross colony produced an intracross colony, and progeny were genotyped to identify homozygotes for both the mGlu 2 and mGlu 3 null alleles. Founder animals were selected to generate colonies of double knockout mice and wild-type mice that were used in all subsequent experiments.
Generation of dopamine D 2 receptor knockout mice. Mice with selective deletions of dopamine D 2L and D 2S receptors (Taconic Farms) were generated by homologous recombination as previously described in Kelly et al. (1997) . The D 2 dopamine receptor targeting vector was electroporated into the D3 ES cell line (Doetschman et al., 1985) , and correctly targeted ES cells were injected into embryonic day 3.5 B6 blastocysts, as described previously (Rubinstein et al., 1996) . Mice used in this study were congenic N5 generated by back- crossing to the B6 strain for five generations. Wild-type C57BL/6J mice were obtained from Taconic Farms.
Assessment of locomotor behavior. Behaviors were monitored in transparent, plastic shoebox cages with dimensions of 45 ϫ 25 ϫ 20 cm, a 1-cm depth of wood chips as bedding, and a plastic cage top. These items were placed in a rectangular frame containing a grid of 12 photocell beams in an 8 ϫ 4 configuration (Kinder Scientific, Poway, CA) that was positioned 2.5 cm from the floor of the cage for the detection of body movements (ambulations) and recorded by computer for analysis. Mice were initially acclimated to a plastic shoebox cage for 15 min before being given an intraperitoneal injection of LY379268 or raclopride or sterile water. After an additional 30 min, the mice were administered an intraperitoneal injection of sterile water or PCP. Motor activity was monitored for 60 min after the injection of PCP. The same test paradigm was followed for AMP treatment. All drugs were mixed fresh before use and administered intraperitoneally. Mice were dosed with a volume of 10 ml/kg. Software analysis of beam breaks, under the definitions of Hamilton Kinder, resulted in the measurement of three different parameters: ambulations (pattern of beam breaks indicating that the animal has relocated its entire body), distance moved (cm Ϫ1 ), and time at rest (total seconds in a 60-min session in which no new beams were broken, measured at 1-s intervals). The doses of LY379268 (10 mg/ kg) and raclopride (3 mg/kg) used in these studies were selected based on the results of preliminary studies carried out in our laboratories. Preliminary dose-response studies revealed that raclopride (1-10 mg/kg) and LY379268 (1-30 mg/kg) significantly reversed PCP (7.5 mg/kg) and AMP (5 mg/kg)-evoked behavioral activation in C57BL/6 and (ICR)CD-1 mice.
Dopamine Synthesis Rate in Reserpinized Rats. Eighteen hours before sacrifice, male rats were given vehicle (2 ml/kg sterile saline) or reserpine (5 mg/kg s.c.) and returned to the home cage. The next day, rats were administered vehicle (2 ml/kg sterile saline), 3 mg/kg LY379268, 10 mg/kg LY379268, 10 mg/kg aripiprazole, 30 mg/kg S-(Ϫ)-3-PPP, or 1 mg/kg quinpirole. All drugs were administered 30 min before NSD1015 (100 mg/kg s.c.) except aripiprazole, which was dosed 60 min before NSD1015. Thirty minutes after the administration of NSD1015 (100 mg/kg), the animals were moved to an adjacent room before being sacrificed by decapitation and their brains were removed. Each brain was dissected, and the striatum and nucleus accumbens were removed and frozen on dry ice. In a second experiment, we assessed the ability of LY379268 (10 mg/kg) or haloperidol (0.5 mg/kg) to block S-(Ϫ)-3-PPP (30 mg/kg)-mediated reductions in the dopamine synthesis rate. As found in the previous experiment, male rats were administered 5 mg/kg reserpine s.c.18 h before sacrifice and returned to the home cage. The next day, rats were dosed with vehicle (2 ml/kg sterile saline), 10 mg/kg LY379268, 0.5 mg/kg haloperidol, 30 mg/kg S-(Ϫ)-3-PPP, or the combination of LY379268/S-(Ϫ)-3-PPP or haloperidol/S-(Ϫ)-3-PPP. All drugs were administered 30 min before NSD1015 (100 mg/kg s.c.). Thirty minutes after the administration of NSD1015 (100 mg/kg), the animals were moved to an adjacent room before being sacrificed by decapitation and the brain was removed for dissection. Each brain was dissected, and the striatum and nucleus accumbens were removed and frozen on dry ice. All drugs were mixed fresh before use and administered subcutaneously and dosed with a volume of 2 ml/kg.
Tissue samples were weighed individually and stored at Ϫ80°C in plastic tubes containing 1 ml of radioactivity HCl (0.01 N) and an antioxidant (0.5 mg/ml L-cysteine) until analyzed for DOPA levels. Immediately before analysis, samples were thawed at room temperature and ultrasonicated. After sonication, 100 l of perchloric acid (1.5 M) was added, and the samples were vortexed and stored at 4°C for 60 min. The samples were then centrifuged for 5 min at 12,000 rpm, and the DOPA content of the supernatant was analyzed by HPLC with electrochemical detection. A BDS-Hypersil 5-m C18 analytical column (2 ϫ 150 mm; Thermo Fisher Scientific, Waltham, MA) was used. The mobile phase consisted of 75 mM sodium phosphate monobasic, 50 mg/l 1-octanesulfonic acid sodium salt, 0.5 mM EDTA, and 4% methanol, pH 2.6 (adjusted with phosphoric acid). The flow rate for the analytical column was 0.4 ml/min, which was maintained at 40°C with a column heater. A BAS LC4C electrochemical detector (BAS Bioanalytical Systems, West Lafayette, IN) with a glassy carbon electrode (E ϭ 0.75 V) was used to detect DOPA at a range setting of 5 nA; 20 l was injected onto the column. The data were collected by using an EZChrom chromatography data system (Scientific Software, San Ramon, CA) running on a Hewlett Packard computer, which calculated peak heights and sample concentrations.
Statistical Analysis. Homologous competition of unlabeled domperidone with [
3 H]domperidone binding was used for calculation of the K d and B max using GraphPad Prism, and the IC 50 values from competition curves were determined by nonlinear regression analysis with Excel. Mean and S.E.M. were calculated for animals in each dose group. Neurochemical and behavioral data were analyzed by one-way analysis of variance, and then post hoc comparisons were made by a Bonferroni corrected t test.
Results

Radioligand Binding Studies. [
3 H]Domperidone binding to D 2 receptors has been reported to be able to distinguish agonists from antagonists, based on agonist production of biphasic displacement curves (Seeman et al., 2003 Such displacement is typical of agonists, with the high-affinity component representing the agonist high-affinity state of the receptor, and the lower affinity component representing the agonist low-affinity state. In agreement with a previous report (Seeman et al., 2003) , we found that [ 3 H]domperidone binding can reveal biphasic competition curves with the endogenous agonist dopamine (see Supplemental Fig. 1 .) However, this phenomenon seemed to be dependent upon the membrane source. Thus, rat striatal membranes showed a robust biphasic displacement curve, the cloned human D 2L -expressing membranes showed a small biphasic curve, and the D 2S -expressing membranes showed only a simple monophasic displacement curve to dopamine. In the rat striatal membranes, DA inhibition of Figures 1 and 2 show the results of examining cloned human D 2L and rat striatal membranes, respectively (data with cloned human D 2S is shown in Supplemental Fig. 2 ). As can be seen from these figures, neither LY354740 nor LY379268 produced significant inhibition of binding in any of the membrane prep- 2S and D 2L isoforms of the receptor. As controls, the endogenous agonist dopamine and the partial agonist 3-PPP were included in the assays. Aripiprazole, a very weak partial agonist, was also included. Aripiprazole, although having high affinity for D 2 receptors, has such low efficacy that only certain in vitro assays are able to reveal its partial agonism (Burris et al., 2002) , whereas many assays only see antagonism with aripiprazole (Lawler et al., 1999; Jordan et al., 2007) . In addition to standard [ 35 S]GTP␥S binding assay conditions, assays were also run in parallel with NMDG replacing sodium, a condition that has been shown to enhance the apparent efficacy of D 2 receptor partial agonists in the [
35 S]GTP␥S binding assay (Lin et al., 2006) . Figure 3 shows the effects of the aforementioned compounds on the stimulation of [ 35 Fig. 3A) , and efficacy was increased when NMDG was substituted for NaCl (E max ϭ 74.3% relative to DA; Fig. 3B ). In this clone-expressing D 2L , there was no detectable agonist activity of aripiprazole, LY379268, or LY354740 regardless of the assay conditions.
In the presence of 1 M DA to activate D 2L -mediated [ 35 S]GTP␥S binding, both raclopride and aripiprazole acted as potent full antagonists (Fig. 4) regardless of the buffer conditions. In the presence of NaCl 3-PPP showed some weak antagonist activity (Fig. 4A) , which was not seen in the The compounds were also evaluated at the cloned human D 2S isoform for any potential agonist activity (Supplemental Fig. 3 ). In the presence of 100 nM NaCl or 100 mM NMDG, dopamine showed potent stimulation of [
35 S]GTP␥S binding (EC 50 ϭ 123 nM, NaCl; EC 50 ϭ 35.7 nM, NMDG). The partial D 2 receptor agonist, 3-PPP, stimulated [
35 S]GTP␥S binding to approximately 45% compared with dopamine in the NaClcontaining buffer, whereas aripiprazole, LY279368, and LY354740 showed no agonist activity. When NMDG was substituted for NaCl, the efficacy of 3-PPP increased to approximately 88% compared with dopamine. Aripiprazole showed a slight trend toward agonist activity, but neither LY279368 nor LY354740 showed any agonist stimulation even in the presence of NMDG.
In cloned D 2S receptors, the antagonists aripiprazole and raclopride both potently inhibited the ability of 1 M DA to stimulate [
35 S]GTP␥S binding in the presence of either NaCl or NMDG in the buffer. Neither 3-PPP, LY379268, nor LY354740 produced measurable antagonism of DA-mediated stimulation of [
35 S]GTP␥S binding in the buffer containing NMDG ( Supplemental Fig. 4 ). In the NaCl-containing buffer, 3-PPP showed a trend toward inhibition of DA-mediated stimulation of [ 35 S]GTP␥S binding, with a moderately good fit by nonlinear regression (R 2 ϭ 0.5153). However, the LY379268 and LY354740 data points in the NaCl-containing buffer showed only poor fits by nonlinear regression (R 2 ϭ 0.1208 and 0.1914, respectively) with the 95% confidence limits for the curve top estimates overlapping those of the bottom estimates, indicating no significant effect of these compounds on DA-stimulated binding.
In Vivo D 2 Receptor Occupancy by LC/MS/MS. The mGlu 2/3 receptor agonists LY379268 and LY354740 monohydrate did not exhibit significant DA D 2 occupancy in the rat 60 min after intraperitoneal administration (Table 1) . However, aripiprazole occupied D 2 receptors in vivo in a dosedependent fashion after oral gavage (Table 1) . High levels of DA D 2 receptor occupancy, 55, 89, and 93%, were achieved after aripiprazole at doses of 10, 30, and 60 mg/kg 90 min after oral administration.
Effects on LY379268 and Raclopride on PCP or AMPInduced Hyperlocomotor Activity in mGlu 2/3 Receptor Knockout Mice. LY379268 (10 mg/kg) and raclopride (3 mg/kg) were tested for their ability to reverse PCP (7.5 mg/ kg) and amphetamine (5 mg/kg)-evoked behaviors in mGlu 2/3 receptor-deficient mice and their respective wild-type controls. Basal locomotor activity, PCP (7.5 mg/kg), or amphetamine (5 mg/kg)-induced behavioral activation did not show statistically significant differences between the wild-type or mGlu 2/3 receptor knockout animals (Fig. 5, top) . Whereas LY379268 (10 mg/kg) produced a highly significant reversal of PCP (7.5 mg/kg)-induced ambulations in wild-type mice (P Ͻ 0.05), the compound was unable to block PCP-evoked increases in ambulatory activity in mGlu 2/3 receptor-deficient mice (Fig. 5, top) . The selective dopamine D 2 /D 3 receptor antagonist raclopride attenuated PCP-evoked locomotor activation at 3 mg/kg in both the mGlu 2/3 receptor-deficient mice and their wild-type controls (P Ͻ 0.05 in both cases). Pretreatment with the mGlu 2/3 receptor agonist LY379268 (10 mg/kg) or raclopride (3 mg/kg) significantly blocked amphetamine-induced hyperlocomotion (Fig. 5, bottom) in the wild-type animals (P Ͻ 0.05 in both cases). However, 
TABLE 1
In vivo rat dopamine D 2 receptor occupancy using LC/MS/MS for LY379268, LY317206, aripiprazole, and haloperidol LY379268 (1-10 mg/kg), LY354740 (10 -60 mg/kg), or aripiprazole (10 -60 mg/kg) was administered 60 min or 90 min before the intravenous injection of the occupancy tracer raclopride (3 g/kg). Animals (n ϭ 4 -5 animals per group) were sacrificed 15 min after the intravenous administration of the raclopride tracer. Haloperidol data are taken from a previously published report by Barth et al. (2006) . jpet.aspetjournals.org LY379268 was without effect on amphetamine-induced hyperactivity in the mGlu 2/3 receptor-deficient mice. In contrast, raclopride was able to fully block amphetamine-induced hyperactivation in mGlu 2/3 receptor-deficient mice (P Ͻ 0.05). Effects on LY379268 and Raclopride on PCP or AMPInduced Hyperlocomotor Activity in DA D 2 Receptor Knockout Mice. Basal locomotor activity levels were not significantly different between the D 2 receptor knockout mice and the wild-type controls; however, the hyperlocomotor response to both PCP (7.5 mg/kg) and AMP (5 mg/kg) was significantly attenuated in the D 2 receptor knockout mice compared with the corresponding wild-type animals (Fig. 6) . Pretreatment with the mGlu 2/3 receptor agonist LY379268 (10 mg/kg) significantly reversed PCP-evoked increase in locomotor behavior in mice lacking dopamine D 2 receptors and their respective wild-type control animals. However, raclopride (3 mg/kg) was only effective at reversing PCPevoked hyperlocomotor activity in the wild-type control animals. Whereas LY379268 (10 mg/kg) produced a highly significant reversal of AMP (5 mg/kg)-induced ambulations in both the wild-type (P Ͻ 0.05) and D 2 receptor knockout mice (P Ͻ 0.05), the selective D 2 /D 3 receptor antagonist raclopride was only able to block AMP-evoked increases in ambulatory activity in the wild-type animals. Raclopride was without effect on the locomotor-stimulating effects of AMP (5 mg/kg) in D 2 receptor-deficient mice.
Effect of LY379268 and DA Agonists on the DA Synthesis Rate in the Striatum and Nucleus Accumbens. The administration of reserpine (5 mg/kg) to male rats significantly increased the DA synthesis rate, measured in vivo as DOPA accumulation, approximately 2-fold in the striatum (Fig. 7, top) and the nucleus accumbens (Fig. 7, bottom) . Consistent with previous reports, the DA agonist quinpirole (1 mg/kg) and the partial DA agonist S-(Ϫ)-3-PPP (30 mg/kg) significantly decreased DOPA accumulation in the striatum (79 and 67%, respectively; P Ͻ 0.01) and the nucleus accumbens (62 and 53.6%, respectively; P Ͻ 0.01). The weak partial DA agonist aripiprazole also significantly decreased DOPA accumulation in both the striatum (31%; P Ͻ 0.01) and nucleus accumbens (30%; P Ͻ 0.01); however, aripiprazole- Fig. 6 . Effect of LY379268 (10 mg/kg) or raclopride (3 mg/kg) on (top) PCP-(7.5 mg/kg) (bottom) and amphetamine (5 mg/kg)-evoked behaviors in wild-type and DA D 2 receptor knockout mice. LY379268 or raclopride was administered (intraperitoneally) 30 min before PCP or AMP intraperitoneal injection; behaviors were monitored over a 60-min period immediately after injection of PCP, AMP, or vehicle. Data (mean Ϯ S.E.M.) are presented as total numbers of behaviors expressed during 60 min; n ϭ 8 mice. ‫,ء‬ P Ͻ 0.05 compared with the corresponding vehicle/ AMP control. Figure 8 shows the effect of haloperidol (0.5 mg/kg) or LY379268 (10 mg/kg) on S-(Ϫ)-3-PPP-mediated reductions in DOPA content. As in the previous study, the administration of S-(Ϫ)-3-PPP (30 mg/kg) significantly reduced striatal (Fig. 8, top ) and nucleus accumbens (Fig. 8, bottom) DOPA accumulation in reserpinized rats. This reduction was significantly blocked by the coadministration of the D 2 receptor antagonist haloperidol (P Ͻ 0.01). In contrast, S-(Ϫ)-3-PPP (30 mg/kg)-mediated reductions in striatal and accumbens DOPA were unaffected by the coadministered of the selective mGlu 2/3 receptor agonist LY379268 (10 mg/kg).
Discussion
The goal of the present work was to understand the interaction of LY379268 and LY354740 with dopamine D 2 receptors that was reported by Seeman and co-workers (Seeman and Guan, 2008; In parallel assays substituting NMDG for NaCl in the assays, a condition reported to enhance partial agonist efficacy in in vitro assays (Lin et al., 2006) , an increase in the efficacy of 3-PPP was seen. However, no agonist activity of either LY354740 or LY379268 was observed in either assay condition. It should be pointed out that aripiprazole, which has been reported to be a D 2 receptor partial agonist with very low efficacy, also showed no significant agonist activity in these assays. Depending on the sensitivity of the assay, aripiprazole is reported as an antagonist or a low-efficacy partial agonist (Lawler et al., 1999; Burris et al., 2002; Jordan et al., 2007) in the literature. Thus, if LY354740 or LY379268 were very low-efficacy partial agonists, on the order of aripiprazole, they would not have been picked up in the [ Having failed to replicate the in vitro findings of Seeman and co-workers (2008), we designed a series of neurochemical and behavioral studies to examine the possible direct interactions with D 2 receptors by mGlu 2/3 receptor agonists in vivo. We used an LC/MS/MS-based receptor occupancy method (Chernet et al., 2005; Barth et al., 2006) to determine the interaction of compounds with the D 2 receptor in the rat striatum. In agreement with previous studies (Natesan et al., 2006) , the partial D 2 receptor agonist aripiprazole (10 -60 mg/kg) dose-dependently occupied D 2 receptors in the rat striatum after oral dosing. In marked contrast to aripiprazole, neither LY379269 nor LY354740 demonstrated D 2 receptor occupancy in the rat striatum.
Activation of postsynaptic D 2 receptors, especially the D 2L isoform, is thought to be relevant for locomotor activity (Usiello et al., 2000; Wang et al., 2000; Xu et al., 2002; Lindgren et al., 2003) . Mice with a targeted deletion of D 2L receptors show reduced levels of locomotor and rearing behaviors and appear to be less sensitive to the locomotorsuppressing and cataleptic effects of D 2 receptor antagonists (Usiello et al., 2000; Wang et al., 2000; Xu et al., 2002) . We investigated the relative contribution of mGlu 2/3 receptors and D 2 receptors in the efficacy of LY379268 and raclopride in the PCP and AMP-evoked hyperlocomotor models of psychosis. Administration of PCP or AMP increased locomotor activity in wild-type animals, mGlu 2/3 receptor knockout mice, and D 2 receptor knockout mice. The mGlu 2/3 receptor agonist LY379268 blocked both PCP and AMP-induced hyperactivity in wild-type mice and mice lacking D 2 receptors. However, the efficacy of LY379268 against both psychostimulants was lost in mGlu 2/3 receptor-deficient animals. As expected, the selective D 2 /D 3 receptor antagonist raclopride was equally effective at reversing PCP and AMP-induced locomotor effects in both wild-type and mGlu 2/3 receptordeficient mice; however, the effects of raclopride were lost in D 2 receptor knockout mice. These data are in agreement with previous studies in mice demonstrating that the effects of mGlu 2/3 receptor agonists in psychostimulant models of psychosis are dependent on functional mGlu 2 receptors (Patil et al., 2007; Fell et al., 2008; Woolley et al., 2008) and not mediated through a direct interaction with D 2L receptors in vivo.
To further evaluate the direct effects of mGlu 2/3 receptor agonists at D 2 receptors, we used a dopamine-depleted (reserpinized) animal preparation, which is a particularly sensitive assay for in vivo D 2 agonist effects and is also sensitive to partial DA agonists with low intrinsic activity due to the development of supersensitive receptors (or increases in receptor reserve) after prolonged synaptic depletion of DA (Carlsson, 1983; Hjorth et al., 1988) . Under these conditions, the mGlu 2/3 receptor agonist LY379268 was without effect on striatal or accumbens DOPA accumulation at either 3 or 10 mg/kg. In contrast, the partial D 2 receptor agonists aripiprazole or S-(Ϫ)-3-PPP and the full D 2 agonist quinpirole reduced both striatal and accumbens DOPA accumulation, consistent with their intrinsic activity at the D 2 receptor (Hjorth et al., 1988; Svensson et al., 1991; Iñ iguez et al., 2008) . In a second experiment, we assessed the ability of LY379268 or the D 2 /D 3 antagonist haloperidol to block partial D 2 agonistmediated reductions in DOPA accumulation in reserpinized rats. Whereas haloperidol significantly blocked the effects of the partial agonist S-(Ϫ)-3-PPP on DOPA accumulation in the striatum and nucleus accumbens, the mGlu 2/3 receptor agonist LY379268 was without effect on the reductions in DOPA accumulation. Taken together, these data demonstrate that LY379268 does not have obvious direct agonist (either full or partial agonist) or antagonist effects at the D 2S receptor in vivo.
The discrepancies between the findings in the current work and those reported by Seeman and co-workers (Seeman and Guan, 2008; are puzzling. In a recent meeting abstract, Zysk et al. (2008) could find no
